Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
T. Koga, Kenichi Suda, Toshio Fujino, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 8, pp. 1321-1332
Open Access | Times Cited: 171

Showing 1-25 of 171 citing articles:

KRAS mutation: from undruggable to druggable in cancer
Lamei Huang, Zhixing Guo, Fang Wang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 585
The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar, Vamsidhar Velcheti, Benjamin G. Neel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 637-655
Open Access | Times Cited: 300
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Marco H. Hofmann, Daniel Gerlach, Sandra Misale, et al.
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 924-937
Open Access | Times Cited: 195
The KRAS-G12C inhibitor: activity and resistance
Jiao Liu, Rui Kang, Daolin Tang
Cancer Gene Therapy (2021) Vol. 29, Iss. 7, pp. 875-878
Open Access | Times Cited: 129
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 128
Recent advances in non-small cell lung cancer targeted therapy; an update review
Mahmood Araghi, Reza Mannani, Ali Heidarnejad maleki, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 127
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Tianyi Zhang, Yanxian Ren, Pengfei Yang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 10
Open Access | Times Cited: 92
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Andreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Cancer Discovery (2022) Vol. 12, Iss. 6, pp. 1500-1517
Open Access | Times Cited: 91
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy
Ziyang Zhang, Peter J. Rohweder, Chayanid Ongpipattanakul, et al.
Cancer Cell (2022) Vol. 40, Iss. 9, pp. 1060-1069.e7
Open Access | Times Cited: 91
Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers
Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, et al.
Science Advances (2022) Vol. 8, Iss. 29
Open Access | Times Cited: 86
Adagrasib: First Approval
Sohita Dhillon
Drugs (2023) Vol. 83, Iss. 3, pp. 275-285
Closed Access | Times Cited: 82
KRAS is vulnerable to reversible switch-II pocket engagement in cells
James D. Vasta, D. Matthew Peacock, Qinheng Zheng, et al.
Nature Chemical Biology (2022) Vol. 18, Iss. 6, pp. 596-604
Open Access | Times Cited: 75
Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
Adnin Ashrafi, Zakia Akter, Pouya Modareszadeh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4562-4562
Open Access | Times Cited: 68
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
E O'Sullivan, Anna Keogh, Brian E. Henderson, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1635-1635
Open Access | Times Cited: 45
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 32
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It
Jiayu Zou, Li Wang, Hailin Tang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13335-13335
Open Access | Times Cited: 79
JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors
Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16173-16203
Closed Access | Times Cited: 64
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 60
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Damien Reita, L. Pabst, Erwan Pencreach, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1321-1321
Open Access | Times Cited: 60
Classification ofKRAS-Activating Mutations and the Implications for Therapeutic Intervention
Christian W. Johnson, Deborah L. Burkhart, Kevin M. Haigis
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 913-923
Open Access | Times Cited: 60
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Misako Nagasaka, Bindu Potugari, Alexis Nguyen, et al.
Cancer Treatment Reviews (2021) Vol. 101, pp. 102309-102309
Open Access | Times Cited: 56
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Takamitsu Hattori, Lorenzo Maso, Kiyomi Y. Araki, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 132-145
Open Access | Times Cited: 52
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Anne-Laure Désage, Camille Léonce, Aurélie Swalduz, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 47
Page 1 - Next Page

Scroll to top